DE69430940T2 - Methode zur Behandlung von resistenten Neoplasmen - Google Patents

Methode zur Behandlung von resistenten Neoplasmen

Info

Publication number
DE69430940T2
DE69430940T2 DE69430940T DE69430940T DE69430940T2 DE 69430940 T2 DE69430940 T2 DE 69430940T2 DE 69430940 T DE69430940 T DE 69430940T DE 69430940 T DE69430940 T DE 69430940T DE 69430940 T2 DE69430940 T2 DE 69430940T2
Authority
DE
Germany
Prior art keywords
chem
treating resistant
resistant neoplasms
neoplasms
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430940T
Other languages
English (en)
Other versions
DE69430940D1 (de
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
James Jacob Starling
Mark Alan Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69430940D1 publication Critical patent/DE69430940D1/de
Publication of DE69430940T2 publication Critical patent/DE69430940T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DE69430940T 1993-10-15 1994-10-13 Methode zur Behandlung von resistenten Neoplasmen Expired - Fee Related DE69430940T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13767893A 1993-10-15 1993-10-15

Publications (2)

Publication Number Publication Date
DE69430940D1 DE69430940D1 (de) 2002-08-14
DE69430940T2 true DE69430940T2 (de) 2003-04-03

Family

ID=22478575

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430940T Expired - Fee Related DE69430940T2 (de) 1993-10-15 1994-10-13 Methode zur Behandlung von resistenten Neoplasmen

Country Status (17)

Country Link
EP (1) EP0652004B1 (de)
JP (1) JPH07149638A (de)
KR (1) KR950010891A (de)
CN (1) CN1108094A (de)
AT (1) ATE220323T1 (de)
AU (1) AU670518B2 (de)
CA (1) CA2118096A1 (de)
CZ (1) CZ253694A3 (de)
DE (1) DE69430940T2 (de)
DK (1) DK0652004T3 (de)
ES (1) ES2179063T3 (de)
HU (1) HUT71237A (de)
IL (1) IL111287A0 (de)
NO (1) NO943874L (de)
PT (1) PT652004E (de)
RU (1) RU94037233A (de)
ZA (1) ZA948025B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
CZ51897A3 (en) * 1994-08-22 1997-06-11 Lilly Co Eli Inhibition method of endometrial cancer
DK0771201T3 (da) * 1994-08-22 2001-05-07 Lilly Co Eli Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
CA2236543A1 (en) * 1995-11-07 1997-05-15 Alan David Palkowitz Methods for treating resistant tumors
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
AU707675B2 (en) * 1996-01-29 1999-07-15 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
WO2002089801A1 (en) * 2001-05-10 2002-11-14 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostave cancer
US7425565B2 (en) 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
IL111287A0 (en) 1994-12-29
PT652004E (pt) 2002-10-31
HUT71237A (en) 1995-11-28
ATE220323T1 (de) 2002-07-15
NO943874D0 (no) 1994-10-13
NO943874L (no) 1995-04-18
ZA948025B (en) 1996-04-15
JPH07149638A (ja) 1995-06-13
EP0652004B1 (de) 2002-07-10
HU9402961D0 (en) 1995-02-28
RU94037233A (ru) 1996-08-27
CZ253694A3 (en) 1995-05-17
ES2179063T3 (es) 2003-01-16
EP0652004A1 (de) 1995-05-10
AU7578694A (en) 1995-05-04
CN1108094A (zh) 1995-09-13
DE69430940D1 (de) 2002-08-14
KR950010891A (ko) 1995-05-15
CA2118096A1 (en) 1995-04-16
AU670518B2 (en) 1996-07-18
DK0652004T3 (da) 2002-09-02

Similar Documents

Publication Publication Date Title
ATE150308T1 (de) Hemmung von thrombin
ATE203404T1 (de) Methode zur hemmung der endometriose
ATE220323T1 (de) Methode zur behandlung von resistenten neoplasmen
ATE150307T1 (de) Hemmung von seborrhoe und akne
ES2172525T3 (es) Inhibicion de la fibrosis uterina.
DE69426855D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung des Knorpelabbaus
DE69428325D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee